<p>維京治療公司（NASDAQ:VKTX - 獲取免費報告）於週三發佈了季度財報。這家生物技術公司報告的季度每股收益為（$0.41），低於分析師一致預期的（$0.34），差距為（$0.07），據 Zacks 報道。</p>
<p>獲取 <strong>維京治療</strong> 的提醒：</p>
<h2>維京治療股價上漲 1.4%</h2>
<ul>
<li>維京治療股票上漲但難以保持漲幅</li>
</ul>
<p>週三，VKTX 的交易價格上漲了$0.36，達到$25.84。該公司交易了 4,145,398 股股票，而其平均交易量為 4,045,729 股。該股票的 50 日移動平均價格為$26.75，200 日移動平均價格為$41.30。維京治療的 1 年最低價為$18.92，1 年最高價為$81.86。該公司的市值為 29 億美元，市盈率為-25.84，貝塔值為 0.84。</p>
<h2>華爾街分析師觀點</h2>
<p>VKTX 已成為多份研究分析報告的主題。HC Wainwright 在 4 月 17 日的研究報告中重申了 “買入” 評級，並設定了維京治療股票的目標價為$102.00。高盛集團在 4 月 8 日的報告中開始覆蓋維京治療股票，給予 “中性” 評級，目標價為$30.00。B. Riley 在 2 月 7 日的報告中重申了 “買入” 評級，並將維京治療股票的目標價從$109.00 下調至$96.00。加拿大豐業銀行在 2 月 13 日的研究報告中開始覆蓋維京治療，設定了 “行業表現優於大盤” 評級和$102.00 的目標價。最後，Maxim Group 在 2 月 7 日的報告中將維京治療股票的目標價從$120.00 下調至$70.00，並給予 “買入” 評級。一位分析師給予該股票 “賣出” 評級，兩位分析師給予 “持有” 評級，十位分析師給予 “買入” 評級，一位分析師給予 “強烈買入” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，共識目標價為$89.75。</p>
<ul>
<li>目前哪個醫療保健股票是最佳買入？</li>
</ul>
<p><strong>獲取我們對維京治療的最新股票分析</strong></p>
<h2>維京治療的內部活動</h2>
<p>在其他新聞中，董事 Sarah Kathryn Rouan 在 3 月 31 日的交易中購買了 1,240 股該公司的股票。每股購買價格為$24.15，總價值為$29,946.00。購買後，該董事現在直接擁有 1,240 股該公司的股票，價值約為$29,946。這代表了其持股的∞增長。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。4.70% 的股票由內部人士持有。</p>
<h2>關於維京治療</h2>
<p>（獲取免費報告）</p>
<ul>
<li>MarketBeat 週迴顧 – 03/17 - 03/21</li>
</ul>
<p>維京治療公司是一家臨牀階段的生物製藥公司，專注於開發用於代謝和內分泌疾病的新療法。該公司的主要藥物候選者是 VK2809，一種口服可用的選擇性甲狀腺激素受體β（TRß）激動劑，目前正在進行 IIb 期臨牀試驗，以治療經活檢確認的非酒精性脂肪性肝炎以及非酒精性脂肪肝病（NAFLD）。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票比維京治療更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>IBM 的第一季度收益能否引發股票的突破？</li>
<li>什麼是低市盈率，它對投資者有什麼啓示？</li>
<li>標普 500 和納斯達克 100 出現死亡交叉——你應該擔心嗎？</li>
<li>哪裏可以找到財報電話會議的記錄</li>
<li>基本面良好，這五隻股票卻被拋售</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在維京治療嗎？</h2>
<p>在考慮維京治療之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而維京治療並不在名單上。</p>
<p>雖然維京治療目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Viking治療

<p>Viking Therapeutics（納斯達克代碼：VKTX）報告的季度每股收益為（$0.41），低於預期$0.07。該股上漲 1.4%，報$25.84，市值為 29 億美元。分析師的評級不一，普遍評級為 “適度買入”，目標價為$89.75。內部交易方面，董事 Sarah Kathryn Rouan 購買了 1,240 股。該公司專注於開發代謝疾病的治療方案，其主要候選藥物 VK2809 正在進行 IIb 期臨牀試驗</p>

<p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07), Zacks reports.</p>
<div class="lb-trans"><p>維京治療公司（NASDAQ:VKTX - 獲取免費報告）於週三發佈了季度財報。這家生物技術公司報告的季度每股收益為（$0.41），低於分析師一致預期的（$0.34），差距為（$0.07），據 Zacks 報道。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>維京治療</strong> 的提醒：</p>
</div><h2>Viking Therapeutics Trading Up 1.4 %</h2>
<div class="lb-trans"><h2>維京治療股價上漲 1.4%</h2>
</div><ul>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>維京治療股票上漲但難以保持漲幅</li>
</ul>
</div><p>VKTX traded up $0.36 during trading on Wednesday, hitting $25.84. 4,145,398 shares of the company's stock were exchanged, compared to its average volume of 4,045,729. The stock has a 50 day moving average price of $26.75 and a 200 day moving average price of $41.30. Viking Therapeutics has a 1 year low of $18.92 and a 1 year high of $81.86. The firm has a market cap of $2.90 billion, a P/E ratio of -25.84 and a beta of 0.84.</p>
<div class="lb-trans"><p>週三，VKTX 的交易價格上漲了$0.36，達到$25.84。該公司交易了 4,145,398 股股票，而其平均交易量為 4,045,729 股。該股票的 50 日移動平均價格為$26.75，200 日移動平均價格為$41.30。維京治療的 1 年最低價為$18.92，1 年最高價為$81.86。該公司的市值為 29 億美元，市盈率為-25.84，貝塔值為 0.84。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>VKTX has been the topic of a number of research analyst reports. HC Wainwright reiterated a &#34;buy&#34; rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Thursday, April 17th. The Goldman Sachs Group began coverage on shares of Viking Therapeutics in a report on Tuesday, April 8th. They issued a &#34;neutral&#34; rating and a $30.00 price target on the stock. B. Riley reiterated a &#34;buy&#34; rating and set a $96.00 target price (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. Scotiabank began coverage on Viking Therapeutics in a research note on Thursday, February 13th. They set a &#34;sector outperform&#34; rating and a $102.00 price objective on the stock. Finally, Maxim Group reduced their target price on shares of Viking Therapeutics from $120.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $89.75.</p>
<div class="lb-trans"><p>VKTX 已成為多份研究分析報告的主題。HC Wainwright 在 4 月 17 日的研究報告中重申了 “買入” 評級，並設定了維京治療股票的目標價為$102.00。高盛集團在 4 月 8 日的報告中開始覆蓋維京治療股票，給予 “中性” 評級，目標價為$30.00。B. Riley 在 2 月 7 日的報告中重申了 “買入” 評級，並將維京治療股票的目標價從$109.00 下調至$96.00。加拿大豐業銀行在 2 月 13 日的研究報告中開始覆蓋維京治療，設定了 “行業表現優於大盤” 評級和$102.00 的目標價。最後，Maxim Group 在 2 月 7 日的報告中將維京治療股票的目標價從$120.00 下調至$70.00，並給予 “買入” 評級。一位分析師給予該股票 “賣出” 評級，兩位分析師給予 “持有” 評級，十位分析師給予 “買入” 評級，一位分析師給予 “強烈買入” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，共識目標價為$89.75。</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪個醫療保健股票是最佳買入？</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on Viking Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們對維京治療的最新股票分析</strong></p>
</div><h2>Insider Activity at Viking Therapeutics</h2>
<div class="lb-trans"><h2>維京治療的內部活動</h2>
</div><p>In other news, Director Sarah Kathryn Rouan purchased 1,240 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average price of $24.15 per share, with a total value of $29,946.00. Following the purchase, the director now directly owns 1,240 shares of the company's stock, valued at approximately $29,946. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.70% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Sarah Kathryn Rouan 在 3 月 31 日的交易中購買了 1,240 股該公司的股票。每股購買價格為$24.15，總價值為$29,946.00。購買後，該董事現在直接擁有 1,240 股該公司的股票，價值約為$29,946。這代表了其持股的∞增長。該交易已在向 SEC 提交的文件中披露，您可以通過此鏈接訪問。4.70% 的股票由內部人士持有。</p>
</div><h2>About Viking Therapeutics</h2>
<div class="lb-trans"><h2>關於維京治療</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><ul>
<li>MarketBeat Week in Review – 03/17 - 03/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 03/17 - 03/21</li>
</ul>
</div><p>Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.</p>
<div class="lb-trans"><p>維京治療公司是一家臨牀階段的生物製藥公司，專注於開發用於代謝和內分泌疾病的新療法。該公司的主要藥物候選者是 VK2809，一種口服可用的選擇性甲狀腺激素受體β（TRß）激動劑，目前正在進行 IIb 期臨牀試驗，以治療經活檢確認的非酒精性脂肪性肝炎以及非酒精性脂肪肝病（NAFLD）。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Viking Therapeutics</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Can IBM’s Q1 Earnings Spark a Breakout for the Stock?</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>S&amp;P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Fundamentally Sound, These 5 Stocks Sold Off Anyway</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比維京治療更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>IBM 的第一季度收益能否引發股票的突破？</li>
<li>什麼是低市盈率，它對投資者有什麼啓示？</li>
<li>標普 500 和納斯達克 100 出現死亡交叉——你應該擔心嗎？</li>
<li>哪裏可以找到財報電話會議的記錄</li>
<li>基本面良好，這五隻股票卻被拋售</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=VKTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Viking Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在維京治療嗎？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮維京治療之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而維京治療並不在名單上。</p>
</div><p>While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然維京治療目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Viking 治療（NASDAQ 代碼：VKTX）公佈了收益結果，每股收益比預期低 0.07 美元